Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report

Sara Al-Rasbi; Juhaina Salim Al-Maqbali; Rajaa Al-Farsi; Moza Ali Al Shukaili; Maryam H. Al-Riyami; Zubaida Al Falahi; Hatem Al Farhan; Abdullah M. Al Alawi

doi:10.12659/AJCR.934399

17 February 2022: Articles

Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report

Unusual clinical course, Challenging differential diagnosis, Diagnostic / therapeutic accidents, Management of emergency care, Unexpected drug reaction , Educational Purpose (only if useful for a systematic review or synthesis)

Sara Al-Rasbi ^A , Juhaina Salim Al-Mqbali ^A* , Rajaa Al-Farsi ^B , Moza Ali Al Shukaili ^B , Maryam H. Al-Riyami ^E , Zubaida Al Falahi ^E , Hatem Al Farhan ^A , Abdullah M. Al Alawi ^A

DOI: 10.12659/AJCR.934399

Am J Case Rep 2022; 23:e934399

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

View HTML version

Figure 6. Trend of troponin T (ng/L) during hospitalization.

Back to the Article

Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report

Your Privacy